Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway

By Roberta Tasso, S. Negrini, Andrea Amateis, F. Indiveri, R. Cancedda, G. Pennesi. European Journal of Immunology, 2005

711 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/e6925a79d40c6fe70d2a2169bd972730a09cdc6f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. N. Singer
2. A. Caplan

In Immunology

1. E. Wherry
2. Rafi Ahmed
3. G. Freeman
4. Arlene H. Sharpe
5. A. Schietinger
6. P. Greenberg
7. D. Pardoll
8. Lieping Chen

In Oncology

1. E. Wherry
2. Rafi Ahmed
3. Arlene H. Sharpe
4. G. Freeman
5. A. Caplan
6. A. Schietinger
7. Lieping Chen
8. P. Greenberg

Citations in the corpus

• Mesenchymal Stem Cells: Mechanisms of Immunomodulation and Homing (2010, neutral): “[ 66 ] .”
• Mesenchymal stem cells: mechanisms of inflammation. (2011, background): “This conclusion resulted from observations that conditioned medium from MSCs activated either singly or in combination with cytokines [IL-1β, tumor necrosis factor α (TNF-α), interferon-γ (IFN-γ)] or by coculture with allogeneic peripheral-blood mononuclear cells (PBMCs) can reduce T cell proliferat”
• The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (2007, background): “In contrast, PD-L1 (also called B7-H1 and CD274) is expressed constitutively on murine T cells, B cells, DCs, macrophages, mesenchymal stem cell”